Abstract
The bilateral intrastriatal injection of D-Ala 2-Met-Enkephalinamide (DALA) at doses of ranging from 12 to 50 μg decreased cyclic-GMP content in the cerebellum and produced catalepsy. These effects were prevented by naltrexone, an opiate receptor antagonist but not by apomorphine, a dopamine agonist. The bilateral injection of DALA in the cerebellum, and substantia nigra neither decreased cerebellar cyclic GMP content nor produced catalepsy. The bilateral injection of DALA (20 ug) into the ventromedial thalamic nuclei caused marked catalepsy but failed to decrease cerebellar cyclic GMP. The results suggest that the effect of DALA on cGMP can be differentiated from the cataleptic response and that it is mediated by an action on opioid receptors located in the striatum, beyond DA receptors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
